Anti-tumor/metastatic activity of β-glucan purified from mutated Saccharomyces cerevisiae

Taek Joon Yoon, Jun Hong Park, Jung Han Kim, Won Ah Choi, Ah Reum Kim, Bo Yeon Won, Seong Sik Won, Tae-Kyu Park and Kwangho Lee

Bio-Food and Drug Research Center, Konkuk University

TEL: =82-43-840-3613, FAX: +82-43-840-3872

Abstract

We here demonstrate the evidence of increased anti-tumor and immunostimulating activities of \(\beta \)-glucan (IS2) purified from mutated Saccharomyces cerevisiae compared to the wild type S. cerevisiae. In experimental lung metastasis of colon26-M3.1 carcinoma or B16-BL6 melanoma cells, prophylactically intravenous (i.v.) administration of β -glucan purified from mutated S. cerevisiae significantly inhibited lung metastasis in a dose-dependant manner. In an assay of liver and spleen metastasis produced by i.v. inoculation of L5178Y-ML25 cells, IS2 also significantly protected the metastasis in CDF1 mice. Furthermore, pretreatment with IS2 2 day before tumor inoculation resulted in a significantly prolonged survival time of tumor-bearing mice, although all mice had virtually succumbed with 36 days after tumor inoculation. In an in vitro cytotoxicity analysis, IS2 at the concentration up to 500 mg/ml did not affect the growth of colon26-M3.1 cells. In contrast, IS2 showed the enhancement of splenocyte proliferating activity in a dose-dependent manner. Peritoneal macrophage stimulated with IS2 produced various cytokines such as IL-1β, TNF-a, IFN-y and IL-12. The depletion of NK cells by injection of rabbit anti-asialo GM1 serum abolished the inhibitory effect of IS2 on lung metastasis of colon26-M3.1 cells. These data suggest that IS2 has antitumor activity to inhibit tumor metastasis, and its antitumor effects is associated with activation of macrophages and NK cells.